News
CGEM
19.60
-0.15%
-0.03
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Barchart · 7h ago
Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH
NASDAQ · 18h ago
Cullinan Therapeutics (CGEM) Wins FDA Backing For CLN 049, Is The Upside Already Priced In?
Simply Wall St · 1d ago
Cullinan Oncology: Buy Rating Reaffirmed with Unchanged $30 Price Target on Robust Pipeline and Strong Cash Position
TipRanks · 2d ago
Weekly Report: what happened at CGEM last week (0803-0807)?
Weekly Report · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Mesoblast Limited (MEOBF), Cullinan Management (CGEM)
TipRanks · 6d ago
Cullinan Maintained at Buy as Advancing Autoimmune and Oncology Pipeline Supports Unchanged $36 Price Target
TipRanks · 6d ago
Cullinan Therapeutics: Q2 Earnings Snapshot
Barchart · 6d ago
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Barchart · 6d ago
Cullinan Therapeutics Reports Tomorrow But Analysts Haven't Lowered Their Targets
Barchart · 08/05 16:06
Will FDA-Backed Registrational Phase 2 for CLN-049 Redefine Cullinan Therapeutics' (CGEM) Narrative?
Simply Wall St · 08/03 11:15
Weekly Report: what happened at CGEM last week (0727-0731)?
Weekly Report · 08/03 09:49
Cullinan Therapeutics Launches Early Trial of Velinotamig in Hard‑to‑Treat Blood Disorders
TipRanks · 07/31 16:30
Wedbush Sticks to Their Buy Rating for Cullinan Management (CGEM)
TipRanks · 07/29 13:49
Cullinan Therapeutics price target raised to $39 from $38 at BTIG
TipRanks · 07/29 11:36
Cullinan Therapeutics Price Target Raised to $39.00/Share From $38.00 by BTIG
Dow Jones · 07/29 10:23
Cullinan Therapeutics Is Maintained at Buy by BTIG
Dow Jones · 07/29 10:23
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $39
Benzinga · 07/29 10:13
Analysts’ Top Healthcare Picks: Kiniksa Pharmaceuticals (KNSA), Cullinan Management (CGEM)
TipRanks · 07/28 15:40
Cullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA
TipRanks · 07/28 11:15
More
Webull provides a variety of real-time CGEM stock news. You can receive the latest news about Cullinan Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About CGEM
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.